歌戈藥業投資興建的現代化GMP制藥企業,以緩控釋制劑類藥物為主,產品涵蓋心腦血管、內分泌、消化、抗過敏、精神、感冒和鎮痛等多個領域
北京紅(hong)林制藥有限公(gong)司是歌戈藥業(ye)(ye)(ye)公(gong)司 (Goe Goe Pharmaceutical Co.)投資興(xing)建的現代(dai)化GMP制藥企業(ye)(ye)(ye),已通過新版GMP認(ren)證,注(zhu)冊資本1580萬美元,擁有先進的緩控釋(shi)技術(shu)(shu),系“高新技術(shu)(shu)企業(ye)(ye)(ye)”。公(gong)司生產基(ji)地座落于(yu)北京市懷柔(rou)區(qu)雁棲工業(ye)(ye)(ye)開發區(qu)。
目前公(gong)司在研新藥項目近十項,其(qi)中(zhong)多(duo)為緩控釋(shi)(shi)制劑(ji)。公(gong)司己注冊中(zhong)國控釋(shi)(shi)技術專利5項,并(bing)擁有(you)(you)進(jin)口智(zhi)能化(hua)(hua)激光打孔(kong)儀等(deng)先進(jin)的生產(chan)設備,產(chan)品(pin)涵蓋心(xin)腦血管(guan)、內分泌、消化(hua)(hua)、抗過(guo)(guo)敏、精(jing)神(shen)、感冒和鎮痛等(deng)多(duo)個領(ling)域。目前公(gong)司正在進(jin)行(xing)一(yi)致(zhi)性評(ping)價品(pin)種(zhong)有(you)(you)5個,其(qi)中(zhong)久保(bao)(bao)(bao)平(ping)®(硝(xiao)苯地(di)平(ping)控釋(shi)(shi)片(pian)(pian)(pian))、樂(le)透福®(格列吡嗪控釋(shi)(shi)片(pian)(pian)(pian))、久保(bao)(bao)(bao)舒(shu)®(苯磺酸(suan)氨氯地(di)平(ping)片(pian)(pian)(pian))、久保(bao)(bao)(bao)芬®(布洛芬緩釋(shi)(shi)膠(jiao)囊)均(jun)已(yi)通(tong)過(guo)(guo)一(yi)致(zhi)性評(ping)價。公(gong)司注重(zhong)人(ren)才的引進(jin)和培養,目前有(you)(you)數名高(gao)級技術支持(chi)(chi)人(ren)員、博士、碩(shuo)士、執業藥師等(deng),并(bing)擁有(you)(you)美國專家管(guan)理團(tuan)隊技術支持(chi)(chi)。